首頁 > 市場調查報告書 > 製藥

全球膀胱過動症治療市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1408982

全球膀胱過動症治療市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global Overactive Bladder Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年01月01日 | 出版商:

Value Market Research | 英文 248 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2030 年，全球膀胱過動症治療市場的市場規模將從 2022 年的 43.3 億美元達到近 65.4 億美元，2023-2030 年研究期間CAGR為 5.29%。

膀胱過動症 (OAB) 的治療涉及多種方法來控制與這種情況相關的症狀。 OAB 的特徵是膀胱壁肌肉突然不自主地收縮，導致頻繁、緊急的排尿需求。該治療旨在緩解症狀並改善個人的生活品質。

市場動態

膀胱過動症 (OAB) 治療市場由幾個關鍵因素驅動。主要原因是 OAB 盛行率不斷上升，特別是在老化人口中，導致對有效治療方案的需求不斷增加。醫學研究和藥物創新的進步發揮著至關重要的作用，標靶藥物的開發可提高療效並減少副作用。人們越來越認知到行為療法和生活方式改變是 OAB 的有效一線治療方法，這進一步塑造了市場。這種向非侵入性方法的轉變有助於擴大行為治療計畫和相關干預措施的市場。在設備和手術技術進步的推動下，對其他治療方法抗藥性的 OAB 病例的神經調節療法和手術干預也影響著市場。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球膀胱過動症治療市場的每個細分市場進行了包容性評估。膀胱過動症治療產業的成長和趨勢為本研究提供了整體方法。

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲膀胱過動症治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。膀胱過動症治療市場的主要參與者包括輝瑞公司、艾伯維公司、安斯泰來製藥公司、美敦力公司、住友製藥美國公司（Urovant Sciences.）、Viatris Inc.、梯瓦製藥工業有限公司、久光製藥Co., Inc.、Macleods Pharmaceuticals Ltd.、Endo International plc。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：膀胱過動症治療公司的競爭格局

膀胱過動症治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

公司股份分析
市場集中度
Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

AbbVie Inc.

公司簡介
公司收入
產品
最近的發展

Astellas Pharma Inc.

公司簡介
公司收入
產品
最近的發展

Medtronic

公司簡介
公司收入
產品
最近的發展

Sumitomo Pharma America Inc.( Urovant Sciences.)

公司簡介
公司收入
產品
最近的發展

Viatris Inc.

公司簡介
公司收入
產品
最近的發展

Teva Pharmaceutical Industries Ltd.

公司簡介
公司收入
產品
最近的發展

Hisamitsu Pharmaceutical Co. Inc

公司簡介
公司收入
產品
最近的發展

Macleods Pharmaceuticals Ltd.

公司簡介
公司收入
產品
最近的發展

Endo International plc

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112113273

The global demand for Overactive Bladder Treatment Market is presumed to reach the market size of nearly USD 6.54 BN by 2030 from USD 4.33 BN in 2022 with a CAGR of 5.29% under the study period 2023 - 2030.

Overactive bladder (OAB) treatment involves various approaches to managing the symptoms associated with this condition. OAB is characterized by a sudden, involuntary contraction of the muscles in the bladder wall, leading to a frequent and urgent need to urinate. The treatment aims to alleviate symptoms and improve the individual's quality of life.

MARKET DYNAMICS

The Overactive Bladder (OAB) Treatment market is driven by several key factors. A primary contributor is the increasing prevalence of OAB, particularly among the aging population, leading to a rising demand for effective treatment options. Advancements in medical research and pharmaceutical innovation play a crucial role, with the development of targeted medications offering improved efficacy and fewer side effects. The market is further shaped by the growing recognition of behavioral therapies and lifestyle modifications as effective first-line treatments for OAB. This shift towards non-invasive approaches contributes to the expansion of the market for behavioral therapy programs and related interventions. Neuromodulation therapies and surgical interventions for OAB cases resistant to other treatments also influence the market, driven by technological advancements in devices and procedures.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of overactive bladder treatment. The growth and trends of overactive bladder treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the overactive bladder treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Anticholinergics
Mirabegron
Botox
Neuromodulation
Other

By Disease Type

Idiopathic Overactive Bladder
Neurogenic Overactive Bladder

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Overactive Bladder Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Overactive Bladder Treatment market include Pfizer, Inc., AbbVie Inc., Astellas Pharma Inc., Medtronic, Sumitomo Pharma America, Inc.( Urovant Sciences.), Viatris Inc., Teva Pharmaceutical Industries Ltd., Hisamitsu Pharmaceutical Co., Inc, Macleods Pharmaceuticals Ltd., Endo International plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . OVERACTIVE BLADDER TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Disease Type
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY TYPE

5.1 Overview by Type
5.2 Historical and Forecast Data
5.3 Analysis by Type
5.4 Anticholinergics Historic and Forecast Sales by Regions
5.5 Mirabegron Historic and Forecast Sales by Regions
5.6 Botox Historic and Forecast Sales by Regions
5.7 Neuromodulation Historic and Forecast Sales by Regions
5.8 Other Historic and Forecast Sales by Regions

6 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY DISEASE TYPE

6.1 Overview by Disease Type
6.2 Historical and Forecast Data
6.3 Analysis by Disease Type
6.4 Idiopathic Overactive Bladder Historic and Forecast Sales by Regions
6.5 Neurogenic Overactive Bladder Historic and Forecast Sales by Regions

7 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1 Overview by Distribution Channel
7.2 Historical and Forecast Data
7.3 Analysis by Distribution Channel
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL OVERACTIVE BLADDER TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE OVERACTIVE BLADDER TREATMENT COMPANIES

9.1. Overactive Bladder Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF OVERACTIVE BLADDER TREATMENT INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Pfizer Inc.
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. AbbVie Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Astellas Pharma Inc.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Medtronic
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Sumitomo Pharma America Inc.( Urovant Sciences.)
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Viatris Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Teva Pharmaceutical Industries Ltd.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Hisamitsu Pharmaceutical Co. Inc
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Macleods Pharmaceuticals Ltd.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Endo International plc
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments